Compare Dyne Therapeutics Inc. Common Stock (DYN) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs VF Corp — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15 (market cap $2.81B), while VF Corp trades at $16.49 (market cap $6.48B). The key difference: VF Corp is far larger — about 2.3× Dyne Therapeutics Inc. Common Stock's market cap, and VF Corp pays a 2.18% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and VF Corp for 64 Days on average.
| DYN | VFC | |
|---|---|---|
Market Cap | $2.81B | $6.48B |
Volume | 2,195,902 | 18,946,837 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $21.55 |
52-Week Low | $14.60 | $12.62 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $2.13B | $10.76B |
Dividend Yield | — | 2.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
VFC trades at $16.07, up 1.77% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported mixed quarterly results, beating in Q4 2025 but missing in subsequent quarters, while revenue declined to $9.5B in 2025 with a net loss of $189.72M. Analyst consensus shows a Hold rating with a $18.33 price target, and the company recently announced a $0.09 dividend for September 2026.
VFC presents a turnaround opportunity with discounted valuation metrics (P/S 0.67) and improving cash flow projections for 2026, but faces significant execution risks from Vans brand weakness and high debt levels. The stock's near-term performance hinges on Q3 2026 earnings delivery and sustained outdoor segment growth offsetting core brand challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
